The Company will commercially launch the FDA-cleared Mazor X platform during the North American Spine Society (NASS) annual meeting which will be held in Boston, Massachusetts, this October. Mazor recently signed a commercial co-promotion and co-development agreement with Medtronic. As part of the agreement, Medtronic has already placed a purchase order for 15 Mazor X systems.
“Mazor X is the culmination of a multi-year development effort to proactively address our target market, surgeon and patient needs for today’s reimbursement environment, by applying multi-disciplinary principles to achieve a Surgical Assurance platform,” commented Ori Hadomi, Chief Executive Officer. “Our pioneering experience in guidance technology, which has been used by hundreds of surgeons to place over 100,000 guided spine implants, has been leveraged in the development of the Mazor X system.”
“The Mazor X platform expands the field of spine surgery from trajectory guidance to assisting surgeons with a total patient treatment strategy. Following our recently formed partnership with Medtronic and the increased market access it provides us, the launch of the Mazor X positions us for accelerated growth and long term leadership in the spine market,” concluded Mr. Hadomi.
“We’ve now got a platform that could help us be more precise, more efficient, and reduce the overall risk rate of spinal surgery,” said Dr. Isador Lieberman from Plano, Texas. “These tools are facilitating the plan and its execution with precision.”
“In my opinion, it [Mazor X] will be the standard of care, no doubt about it,” Dr. Dennis Devito from Atlanta, Georgia added. “This goes beyond just placing an implant. We’re looking at how the whole procedure works.”
More details can be found from Mazor Robotics website.
No comments:
Post a Comment